CollPlant has introduced the recombinant human collagen (rhCollagen)-based bioink platform, Collink.3D 90, for use in different 3D bioprinting applications.
Collink.3D 90 enables faster human cell migration into gel matrices compared to commercial hydrogel, which is widely used for 2D and 3D cell culture.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to the company, cell migration plays an important role in physiological processes, including tissue repair and regeneration.
The new rhCollagen-based bioink platform is complementary to Collink.3D 50, CollPlant’s initial commercial bioink, and provides enhanced mechanical properties to address the additional printing needs of soft and hard tissues.
Initial data indicates that the Collink.3D 90 platform has the potential to act as a superior, animal-free, human cell culture substrate.
The company stated that bioinks are applied to a variety of soft and hard tissue engineering applications.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWith different physiological needs, each tissue or organ requires specific mechanical needs, so the most suitable bioink for a given application must imitate the physical properties of the target tissue or organ.
CollPlant CEO Yehiel Tal said: “We are very excited to continue to broaden our rhCollagen-based bioink offerings, providing our biopharma and academic customers the ability to print a variety of applications.
“We believe our bioinks deliver a favourable alternative to existing commercial bioinks, owing to their high bio-functionality, rheological properties (e.g. controlled viscosity) and high purity.
“In addition to our product pipeline, bioinks are an important and strategic platform that supports CollPlant’s efforts to pursue licensing and collaboration agreements with business partners, and we will continue to introduce new bioinks and innovate in this area.”
The company claims that Collink.3D enables high-resolution, scalable and reproducible 3D bioprinting of scaffolds that precisely mimic human tissue and organs’ physical properties.
It can be used in 3D cell culturing, engineering tissues, tissue modelling for drug discovery and development, and organ implantation in regenerative medicine.
Additionally, the bioink product is compatible with most 3D bioprinting technologies and cell types, including stem cells, induced pluripotent stem cells, endothelial and epithelial cells.
